

**Adult CIRB - Early Phase Emphasis Meeting Agenda**

**March 19, 2024**

---

**I New Study - Initial Review**

**10637**, A Phase 2 Study of Venetoclax in Relapsed Classic or Variant Hairy Cell Leukemia (Version Date 01/30/24)

---

**II New Study - Initial Review**

**10640**, Phase 2 and Biomarker Trial of anti-TIGIT and anti-PDL1 in Patients with Recurrent Glioblastoma (Version Date 02/07/24)

---

**III Continuing Review**

**AMC-110**, Risk-Adapted Therapy for HIV-Associated Anal Cancer (Version Date 08/11/23)

---

**IV Continuing Review**

**10486**, Phase 2 Trial of the Combination of the BET inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients with Molecularly-Selected Solid Tumors (ComBET) (Version Date 09/26/23)

---